Interpretation of which specific groups of people need to ban Atrasentan?

Atrasentan is a potent endothelin receptor antagonist that is widely used in the treatment of various kidney diseases, but not all patients are suitable for this drug. The use of atrasentan should strictly follow the guidance of a doctor, especially for some specific groups of people, special attention needs to be paid to its contraindications and usage restrictions.

First of all, pregnant and lactating women are one of the groups that need to ban atrasentan. According to the pharmacological effects of the drug and animal experimental data, atrasentan may be toxic to the fetus during pregnancy and lead to abnormal fetal development. Therefore, pregnant women should avoid using atrasentan during pregnancy.

Secondly, patients with severe liver function impairment are also contraindicated for atrasentan. Atrasentan is metabolized by the liver. For patients with severely impaired liver function, the use of this drug may increase hepatotoxicity and even cause liver failure. Patients with hepatic insufficiency should have close liver function monitoring or choose other alternative drugs when using this drug. If a patient's liver function abnormalities are severe, doctors usually avoid using atrasentan or, in specific circumstances, make decisions after carefully evaluating the benefits and risks of treatment.

Patients with low blood pressure or a history of heart disease also need to use atrasentan with special caution. Atrasentan can dilate blood vessels and lower blood pressure. For patients with existing hypotension, it may aggravate symptoms and cause dizziness, fainting and other discomforts. In addition, patients with a history of heart disease may be at risk of increased cardiac load when receiving atrasentan, so in this case the drug must be used with caution and detailed evaluation by a professional physician.

Patients with severe edema or fluid retention may be at risk of worsening edema when taking atrasentan. The endothelin antagonism of atrasentan may lead to fluid retention, especially in patients with preexisting fluid retention.

Reference materials:https://www.vanrafia.com/